menu
    • menu

    Find Avanafil manufacturers, exporters & distributors on PharmaCompass

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    23

    API Suppliers

    API Suppliers

    5

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    5

    NDC API

    NDC API

    0

    VMF

    NDC API

    17

    Listed Suppliers

    Other Suppliers

    7INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    27

    Others

    FINISHED DOSAGE FORMULATIONS

    18

    FDF Dossiers

    FDF Dossiers

    6

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    0

    Canada

    Canada

    3

    Australia

    Australia

    0

    South Africa

    South Africa

    4

    Listed Dossiers

    Listed Dossiers

    20DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    57RELATED EXCIPIENT COMPANIES

    107EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    3

    US Patents

    3

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 1,991

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    6

    API

    0

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    24

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 330784-47-9, Stendra, Spedra, Ta 1790, Ta-1790, (s)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
    Molecular Formula
    C23H26ClN7O3
    Molecular Weight
    483.9  g/mol
    InChI Key
    WEAJZXNPAWBCOA-INIZCTEOSA-N
    FDA UNII
    DR5S136IVO
    Avanafil
    Avanafil is an orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, thereby prolonging penile erection.
    Avanafil is a Phosphodiesterase 5 Inhibitor. The mechanism of action of avanafil is as a Phosphodiesterase 5 Inhibitor.
    1 2D Structure

    Avanafil

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
    2.1.2 InChI
    InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
    2.1.3 InChI Key
    WEAJZXNPAWBCOA-INIZCTEOSA-N
    2.1.4 Canonical SMILES
    COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl
    2.1.5 Isomeric SMILES
    COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    DR5S136IVO
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide

    2. Stendra

    2.3.2 Depositor-Supplied Synonyms

    1. 330784-47-9

    2. Stendra

    3. Spedra

    4. Ta 1790

    5. Ta-1790

    6. (s)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

    7. Chebi:66876

    8. Dr5s136ivo

    9. (s)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-pyrimidinylmethyl)carbamoyl]pyrimidine

    10. (s)-4-(3-chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-n-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide

    11. (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-n-(2pyrimidinylmethyl)-5-pyrimidinecarboxamide

    12. 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

    13. 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

    14. 4-((3-chloro-4-methoxybenzyl)amino)-2-((2s)-2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

    15. 5-pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2s)-2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-

    16. Stendra (tn)

    17. Avanafil [usan:inn]

    18. Unii-dr5s136ivo

    19. Zepeed

    20. Ine-5-carboxamide

    21. Spedra (tn)

    22. Avanafil [usan]

    23. Avanafil (usan/inn)

    24. Avanafil [inn]

    25. Avanafil [mi]

    26. Avanafil [vandf]

    27. Avanafil [mart.]

    28. Avanafil [who-dd]

    29. Avanafil 100 Microg/ml In Acetonitrile:dimethylsulfoxide

    30. Schembl118799

    31. Avanafil [orange Book]

    32. Gtpl7448

    33. Chembl1963681

    34. Amy1794

    35. Dtxsid50186727

    36. 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide

    37. Bdbm50036629

    38. Cs1566

    39. Mfcd11977961

    40. S4019

    41. Ta1790

    42. Zinc11677857

    43. Akos024462448

    44. Ccg-229896

    45. Db06237

    46. Vi-0162

    47. Ncgc00386241-01

    48. As-20106

    49. Hy-18252

    50. Sw219217-1

    51. D03217

    52. Ab01565827_02

    53. J-019006

    54. Q2873270

    55. Brd-k65781196-001-01-4

    56. (s)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[n-(2-pyrimidylmethyl)carbamoyl]-pyrimidine

    57. (s)-4-[(3-chlor-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1- Pyrrolidinyl]-n-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamid

    58. 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimid

    59. 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimid Ine-5-carboxamide

    60. Avanafil; (s)-4-chloro-6-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

    61. E6l

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 483.9 g/mol
    Molecular Formula C23H26ClN7O3
    XLogP32.6
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count9
    Exact Mass483.1785654 g/mol
    Monoisotopic Mass483.1785654 g/mol
    Topological Polar Surface Area125 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity642
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameStendra
    PubMed HealthAvanafil (By mouth)
    Drug ClassesErectile Dysfunction Agent
    Drug LabelSTENDRA (avanafil) is a selective inhibitor of cGMP-specific PDE5.Avanafil is designated chemically as (S)-4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide and has the following...
    Active IngredientAvanafil
    Dosage FormTablet
    RouteOral
    Strength200mg; 100mg; 50mg
    Market StatusPrescription
    CompanyVivus

    2 of 2  
    Drug NameStendra
    PubMed HealthAvanafil (By mouth)
    Drug ClassesErectile Dysfunction Agent
    Drug LabelSTENDRA (avanafil) is a selective inhibitor of cGMP-specific PDE5.Avanafil is designated chemically as (S)-4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide and has the following...
    Active IngredientAvanafil
    Dosage FormTablet
    RouteOral
    Strength200mg; 100mg; 50mg
    Market StatusPrescription
    CompanyVivus

    4.2 Drug Indication

    Avanafil is indicated for the treatment of erectile dysfunction.

    FDA Label

    Treatment of erectile dysfunction in adult men.

    In order for Spedra to be effective, sexual stimulation is required.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Avanafil is a strong competitive inhibitor of phosphodiesterase 5 (PDE5) with a demonstrated _in vitro_ IC50 of 5.2 nM. Its inhibitory effects on PDE5 are 100-fold more potent than on PDE6 and >1000-fold more potent than on other PDE enzymes, meaning it is less likely to cause visual disturbances and cardiovascular adverse effects when compared with less selective PDE5 inhibitors such as [sildenafil] and [vardenafil]. It has a relatively quick onset of action allowing for administration as early as 15 minutes prior to sexual activity. PDE5 inhibitors like avanafil can cause significant drug interactions when administered alongside certain antihypertensive agents (e.g. alpha blockers, substantial amounts of alcohol). PDE5 inhibitors have also been associated with the development of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that typically presents as sudden loss of vision in one or both eyes and appears to be more common in patients with a "crowded" optic disc. Patients presenting with any degree of vision loss should immediately discontinue use of all PDE5 inhibitors and seek medical attention. In some jurisdictions, a history of NAION or other degenerative retinal disorders is considered a contraindication to avanafil therapy.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    AVANAFIL
    5.2.2 FDA UNII
    DR5S136IVO
    5.2.3 Pharmacological Classes
    Phosphodiesterase 5 Inhibitors [MoA]; Phosphodiesterase 5 Inhibitor [EPC]
    5.3 ATC Code

    G04BE10

    G04BE10

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    G - Genito urinary system and sex hormones

    G04 - Urologicals

    G04B - Urologicals

    G04BE - Drugs used in erectile dysfunction

    G04BE10 - Avanafil

    5.4 Absorption, Distribution and Excretion

    Absorption

    Avanafil is rapidly absorbed following oral administration (Tmax of 30-45 minutes) and appears to have low to moderate oral bioavailability, though formal studies have not been conducted. Administration with a meal results in a mean delay in Tmax of 1.12 to 1.25 hours, a 39% mean reduction in Cmax, and a negligible effect on AUC.

    Route of Elimination

    Following oral administration, avanafil is extensively metabolized. Approximately 62% of a given dose is excreted as metabolites in the feces and approximately 21% as metabolites in the urine.

    Volume of Distribution

    The apparent volume of distribution of avanafil is 47 to 83 L.

    5.5 Metabolism/Metabolites

    Avanafil is extensively metabolized, primarily by CYP3A4 and to a lesser extent by CYP2C9. There are two major metabolites formed, M4 and M16, which exist in the plasma at concentrations 23% and 29% that of the parent compound, respectively. The M16 metabolite lacks pharmacologic effect, but the M4 metabolite has an inhibitory potency for PDE5 18% that of avanafil and accounts for approximately 4% of the observed pharmacologic activity of avanafil.

    5.6 Biological Half-Life

    Studies have demonstrated variability in the terminal elimination half-life of avanafil, with estimates ranging between 5 - 17 hours.

    5.7 Mechanism of Action

    Avanafil inhibits the cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for the degradation of cGMP in the corpus cavernosum located around the penis. Sexual arousal results in the local release of nitric oxide, which in turn stimulates the enzyme guanylate cyclase to produce cGMP. Elevated levels of cGMP result in local smooth muscle relaxation and increased blood flow to the penis (i.e. an erection). As PDE5 inhibitors like avanafil require the endogenous release of nitric oxide in order to exert their pharmacologic effect, they have no effect on the user in the absence of sexual stimulation/arousal.

    API SUPPLIERS

    read-more
    read-more

    01

    Sanofi

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 28732

    Submission : 2014-10-07

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Contract Pharma
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Century Pharmaceuticals

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #11.0A61
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Century Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Honour Lab Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #6.1B62
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-02-05

    Pay. Date : 2015-12-03

    DMF Number : 30024

    Submission : 2015-12-15

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 69037-0019

    Start Marketing Date : 2012-04-27

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Reyoung pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CAMX
    Not Confirmed
    arrow

    Reyoung pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CAMX
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36175

    Submission : 2021-09-16

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Vivus

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CAMX
    Not Confirmed
    arrow

    Vivus

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CAMX
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 24849

    Submission : 2011-05-19

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    DEAFARMA

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CAMX
    Not Confirmed
    arrow

    DEAFARMA

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CAMX
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Shoolin Pharma Chem

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CAMX
    Not Confirmed
    arrow

    09

    Rakshit Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CAMX
    Not Confirmed
    arrow

    Rakshit Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CAMX
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Hetero Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CAMX
    Not Confirmed
    arrow

    Hetero Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CAMX
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644604200,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734","city":"HYDERABAD","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"BEIRUT","customer":"UNDISCLOSED","customerCountry":"LEBANON","quantity":"22.00","actualQuantity":"22","unit":"KGS","unitRateFc":"1400","totalValueFC":"30390.8","currency":"USD","unitRateINR":103545.45454545454,"date":"12-Feb-2022","totalValueINR":"2278000","totalValueInUsd":"30390.8","indian_port":"HYDERABAD AIR","hs_no":"29321990","bill_no":"8182637","productDescription":"API","marketType":"","country":"LEBANON","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655490600,"product":"AVANAFIL","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"RIYADH","customer":"UNDISCLOSED","customerCountry":"SAUDI ARABIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"3000","totalValueFC":"74100.9","currency":"USD","unitRateINR":231240,"date":"18-Jun-2022","totalValueINR":"5781000","totalValueInUsd":"74100.9","indian_port":"HYDERABAD AIR","hs_no":"29334900","bill_no":"2223780","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1665081000,"product":"PHARMACEUTICAL RAW MATERIAL AVANAFIL (AL","address":"309\/310, HARIKRUPA TOWER, NR. OLD SHARDA MANDIR CROSS ROAD, E","city":"AHMEDABAD","supplier":"JAI RADHE SALES","supplierCountry":"INDIA","foreign_port":"BEIRUT","customer":"UNDISCLOSED","customerCountry":"SYRIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"1700","totalValueFC":"16576.7","currency":"USD","unitRateINR":136400,"date":"07-Oct-2022","totalValueINR":"1364000","totalValueInUsd":"16576.7","indian_port":"AHMEDABAD AIR","hs_no":"29321990","bill_no":"4658586","productDescription":"API","marketType":"","country":"SYRIA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"309\/310, HARIKRUPA TOWER, NR. OLD SHARDA MANDIR CROSS ROAD, E, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668623400,"product":"AVANAFIL","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"JEDDAH","customer":"BATTERJEE PHARMACEUTICAL FACTORY","customerCountry":"SAUDI ARABIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2191.6","totalValueFC":"11023.4","currency":"USD","unitRateINR":179929.20000000001,"date":"17-Nov-2022","totalValueINR":"899646","totalValueInUsd":"11023.4","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4000825","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674757800,"product":"MSN PHARMACEUTICAL PRODUCT NAME AVANAFIL","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"RIYADH","customer":"UNDISCLOSED","customerCountry":"SAUDI ARABIA","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"3000","totalValueFC":"147371.3","currency":"USD","unitRateINR":240980,"date":"27-Jan-2023","totalValueINR":"12049000","totalValueInUsd":"147371.3","indian_port":"HYDERABAD AIR","hs_no":"29334900","bill_no":"7291497","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676917800,"product":"AVANAFIL","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"HAMBURG","customer":"ALDER TRADING FZ LLC","customerCountry":"GERMANY","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"3092.8","totalValueFC":"30669.3","currency":"USD","unitRateINR":253297.79999999999,"date":"21-Feb-2023","totalValueINR":"2532978","totalValueInUsd":"30669.3","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4000129","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683484200,"product":"AVANAFIL","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"BOGOTA","customer":"SEVEN PHARMA COLOMBIA SAS","customerCountry":"COLOMBIA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"2204.2","totalValueFC":"12994.8","currency":"USD","unitRateINR":178210.66666666666,"date":"08-May-2023","totalValueINR":"1069264","totalValueInUsd":"12994.8","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4000353","productDescription":"API","marketType":"","country":"COLOMBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684002600,"product":"MSN PHARMACEUTICAL PRODUCT NAME AVANAFIL","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"18.50","actualQuantity":"18.5","unit":"KGS","unitRateFc":"4455","totalValueFC":"80744.5","currency":"USD","unitRateINR":359135.13513513515,"date":"14-May-2023","totalValueINR":"6644000","totalValueInUsd":"80744.5","indian_port":"HYDERABAD AIR","hs_no":"29334900","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694111400,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"STANDARD CHARTERED BANK","customerCountry":"BANGLADESH","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"1300","totalValueFC":"32069.1","currency":"USD","unitRateINR":106480,"date":"08-Sep-2023","totalValueINR":"2662000","totalValueInUsd":"32069.1","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"3787736","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695061800,"product":"AVANAFIL","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"HAMBURG","customer":"ALDER TRADING FZ LLC","customerCountry":"GERMANY","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"3086.4","totalValueFC":"15281.8","currency":"USD","unitRateINR":253703.20000000001,"date":"19-Sep-2023","totalValueINR":"1268516","totalValueInUsd":"15281.8","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4000761","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697567400,"product":"AVANAFIL","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"BOGOTA","customer":"SEVEN PHARMA COLOMBIA SAS","customerCountry":"COLOMBIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"2209.2","totalValueFC":"21871.5","currency":"USD","unitRateINR":182034.70000000001,"date":"18-Oct-2023","totalValueINR":"1820347","totalValueInUsd":"21871.5","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4000834","productDescription":"API","marketType":"","country":"COLOMBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701714600,"product":"PHARMACEUTICAL RAW MATERIAL-BULK DRUG FOR USE IN PHARMACEUTICAL INDUSTRIES AVANAFIL","address":"708, TIMES SQUARE ARCADE,","city":"AHMEDABAD","supplier":"SKJ HEALTHCARE PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BEIRUT","customer":"UNDISCLOSED","customerCountry":"LEBANON","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"1675","totalValueFC":"24566.6","currency":"USD","unitRateINR":136333.33333333334,"date":"05-Dec-2023","totalValueINR":"2045000","totalValueInUsd":"24566.6","indian_port":"Ahmedabad Air","hs_no":"29321990","bill_no":"5812621","productDescription":"API","marketType":"","country":"LEBANON","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"708, TIMES SQUARE ARCADE,, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707330600,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ASUNCION","customer":"LABORATORIOS GALENO S A","customerCountry":"PARAGUAY","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"1830","totalValueFC":"28547.8","currency":"USD","unitRateINR":148044.75,"date":"08-Feb-2024","totalValueINR":"2368716","totalValueInUsd":"28547.8","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"7374739","productDescription":"API","marketType":"","country":"PARAGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720722600,"product":"AVANAFIL","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"LABORATORIES RECALCINE S A","customerCountry":"CHILE","quantity":"13.00","actualQuantity":"13","unit":"KGS","unitRateFc":"4500","totalValueFC":"57876.4","currency":"USD","unitRateINR":372150,"date":"12-Jul-2024","totalValueINR":"4837950","totalValueInUsd":"57876.4","indian_port":"Hyderabad Air","hs_no":"29334900","bill_no":"2374592","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723573800,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"STANDARD CHARTERED BANK","customerCountry":"BANGLADESH","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"1300","totalValueFC":"38414.5","currency":"USD","unitRateINR":107405,"date":"14-Aug-2024","totalValueINR":"3222150","totalValueInUsd":"38414.5","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"3209241","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726684200,"product":"AVANAFIL","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"LABORATORIES RECALCINE S A","customerCountry":"CHILE","quantity":"13.00","actualQuantity":"13","unit":"KGS","unitRateFc":"4500","totalValueFC":"58045.4","currency":"USD","unitRateINR":374175,"date":"19-Sep-2024","totalValueINR":"4864275","totalValueInUsd":"58045.4","indian_port":"Hyderabad Air","hs_no":"29334900","bill_no":"4148203","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1727980200,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"PHARMANEER DRUGS INC","customerCountry":"TAIWAN","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"2700","totalValueFC":"1237.9","currency":"USD","unitRateINR":208032,"date":"04-Oct-2024","totalValueINR":"104016","totalValueInUsd":"1237.9","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"4570748","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1737484200,"product":"AVANAFIL","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"LABORATORIOS RECALCINE S A","customerCountry":"CHILE","quantity":"13.00","actualQuantity":"13","unit":"KGS","unitRateFc":"4500","totalValueFC":"57937.5","currency":"USD","unitRateINR":384300,"date":"22-Jan-2025","totalValueINR":"4995900","totalValueInUsd":"57937.5","indian_port":"Hyderabad Air","hs_no":"29334900","bill_no":"7505038","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741890600,"product":"AVANAFIL","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"EL QAHIRA (= CAIRO)","customer":"EUROFARMA CHILE","customerCountry":"EGYPT","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"3350","totalValueFC":"6449.5","currency":"USD","unitRateINR":279320.5,"date":"14-Mar-2025","totalValueINR":"558641","totalValueInUsd":"6449.5","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"9004398","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1743791400,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"SAMI PHARMACEUTICALS PVT LTD","customerCountry":"PAKISTAN","quantity":"4.50","actualQuantity":"4.5","unit":"KGS","unitRateFc":"1500","totalValueFC":"6640.3","currency":"USD","unitRateINR":126315.51999999999,"date":"05-Apr-2025","totalValueINR":"568419.84","totalValueInUsd":"6640.3","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"9705689","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1743791400,"product":"PHARMACEUTICAL RAW MATERIAL - AVANAFIL I.H.S (CAS NO. 330784-47-9)","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"TO ORDER","customerCountry":"PAKISTAN","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"1600","totalValueFC":"740.9","currency":"USD","unitRateINR":126838.58,"date":"05-Apr-2025","totalValueINR":"63419.29","totalValueInUsd":"740.9","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9692698","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1744137000,"product":"PHARMACEUTICAL RAW MATERIAL - AVANAFIL IHS (CAS NO. 330784-47-9)","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"TO ORDER","customerCountry":"PAKISTAN","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"3685","totalValueFC":"9015.4","currency":"USD","unitRateINR":308693.34399999998,"date":"09-Apr-2025","totalValueINR":"771733.36","totalValueInUsd":"9015.4","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9810617","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1750185000,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"UNITED BANK LTD","customerCountry":"PAKISTAN","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"1400","totalValueFC":"3382.2","currency":"USD","unitRateINR":116247.424,"date":"18-Jun-2025","totalValueINR":"290618.56","totalValueInUsd":"3382.2","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"2814315","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753813800,"product":"AVANAFIL","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"GENOME PHARMACEUTICALS PVT LIMITE","customerCountry":"PAKISTAN","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"1500","totalValueFC":"718.3","currency":"USD","unitRateINR":123650,"date":"30-Jul-2025","totalValueINR":"61825","totalValueInUsd":"718.3","indian_port":"Hyderabad Air","hs_no":"29321990","bill_no":"4027356","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""}]
    12-Feb-2022
    30-Jul-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Efficacy and Tolerability Study of Avanafil in Russia

    Details:

    Undisclosed


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 20, 2015

    Sanofi Company Banner

    01

    Sanofi

    France
    arrow
    ChemOutsourcing
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Efficacy and Tolerability Study of Avanafil in Russia

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 20, 2015

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)

    Details:

    STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Auxilium Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 19, 2022

    blank

    02

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Auxilium Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension St...

    Details : STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 19, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRA (Avanafil) to the Uni...

    Details:

    The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the STENDRA (avanafil) tablets, to the United States, and is expected to provide both cost savings and increase in gross margin.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Undisclosed

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership January 24, 2022

    blank

    03

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of E...

    Details : The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the STENDRA (avanafil) tablets, to the United States, and is expected to provide both cost savings and increase in gross margin.

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 24, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Petros Pharmaceuticals Announces Closing of $10 Million Offering

    Details:

    Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of Petros Pharmaceuticals' men's health platform including Stendra and for working capital and general corporate purposes.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Katalyst Securities

    Deal Size: $10.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering November 30, 2021

    blank

    04

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Katalyst Securities

    Deal Size : $10.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Petros Pharmaceuticals Announces Closing of $10 Million Offering

    Details : Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of Petros Pharmaceuticals' men's health platform including Stendra and for working capital and general corporate purposes.

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 30, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering

    Details:

    Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform which includes enhancing the position of STENDRA, and for working capital and general corporate purposes.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Katalyst Securities

    Deal Size: $5.7 million Upfront Cash: Undisclosed

    Deal Type: Public Offering October 19, 2021

    blank

    05

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Katalyst Securities

    Deal Size : $5.7 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering

    Details : Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform which includes enhancing the position of STENDRA, and for working capital and general corporate purposes.

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 19, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Meeting to Petros Pharma Discuss Label Expansion of Drug STENDRA®

    Details:

    Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 27, 2021

    blank

    06

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Meeting to Petros Pharma Discuss Label Expansion of Drug STENDRA®

    Details : Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 27, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Petros Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication

    Details:

    The Company has initiated a Phase 2 study, which is more significant & Label Comprehension Study that will include low health literacy individuals as part of a multi-step process to develop the behavioral study evidence for FDA to evaluate Stendra for possible OTC designation.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 13, 2021

    blank

    07

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Petros Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Er...

    Details : The Company has initiated a Phase 2 study, which is more significant & Label Comprehension Study that will include low health literacy individuals as part of a multi-step process to develop the behavioral study evidence for FDA to evaluate Stendra for po...

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 13, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet ...

    Details:

    Further expanding the partnership, the companies announce the availability of additional dosages of STENDRA in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Hims & Hers Health

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 11, 2021

    blank

    08

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Hims & Hers Health

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. G...

    Details : Further expanding the partnership, the companies announce the availability of additional dosages of STENDRA in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    March 11, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

    Details:

    Petros' cornerstone product would be Metuchen's Stendra® for erectile dysfunction. Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring various men's health products.


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Stendra

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Neurotrope

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Merger May 18, 2020

    blank

    09

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Petros Pharmaceuticals

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Neurotrope

    Deal Size : Undisclosed

    Deal Type : Merger

    DEALS_DEV arrow-down

    Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, ...

    Details : Petros' cornerstone product would be Metuchen's Stendra® for erectile dysfunction. Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring variou...

    Product Name : Stendra

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 18, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety Study Looking at the Effects of Stendra on Vision

    Details:

    Undisclosed


    Lead Product(s): Avanafil,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 10, 2014

    blank

    10

    Vivus

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Vivus

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avanafil,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety Study Looking at the Effects of Stendra on Vision

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 10, 2014

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 100MG

    USFDA APPLICATION NUMBER - 202276

    read-more

    DOSAGE - TABLET;ORAL - 200MG

    USFDA APPLICATION NUMBER - 202276

    read-more

    DOSAGE - TABLET;ORAL - 50MG

    USFDA APPLICATION NUMBER - 202276

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 330784-47-9 / Avanafil API manufacturers, exporters & distributors?

    Avanafil manufacturers, exporters & distributors 1

    21

    PharmaCompass offers a list of Avanafil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Avanafil manufacturer or Avanafil supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Avanafil manufacturer or Avanafil supplier.

    PharmaCompass also assists you with knowing the Avanafil API Price utilized in the formulation of products. Avanafil API Price is not always fixed or binding as the Avanafil Price is obtained through a variety of data sources. The Avanafil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Avanafil

    Synonyms

    330784-47-9, Stendra, Spedra, Ta 1790, Ta-1790, (s)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

    Cas Number

    330784-47-9

    Unique Ingredient Identifier (UNII)

    DR5S136IVO

    About Avanafil

    Avanafil is an orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, thereby prolonging penile erection.

    stendra Manufacturers

    A stendra manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of stendra, including repackagers and relabelers. The FDA regulates stendra manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. stendra API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of stendra manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    stendra Suppliers

    A stendra supplier is an individual or a company that provides stendra active pharmaceutical ingredient (API) or stendra finished formulations upon request. The stendra suppliers may include stendra API manufacturers, exporters, distributors and traders.

    click here to find a list of stendra suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    stendra USDMF

    A stendra DMF (Drug Master File) is a document detailing the whole manufacturing process of stendra active pharmaceutical ingredient (API) in detail. Different forms of stendra DMFs exist exist since differing nations have different regulations, such as stendra USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A stendra DMF submitted to regulatory agencies in the US is known as a USDMF. stendra USDMF includes data on stendra's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The stendra USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of stendra suppliers with USDMF on PharmaCompass.

    stendra WC

    A stendra written confirmation (stendra WC) is an official document issued by a regulatory agency to a stendra manufacturer, verifying that the manufacturing facility of a stendra active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting stendra APIs or stendra finished pharmaceutical products to another nation, regulatory agencies frequently require a stendra WC (written confirmation) as part of the regulatory process.

    click here to find a list of stendra suppliers with Written Confirmation (WC) on PharmaCompass.

    stendra NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing stendra as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for stendra API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture stendra as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain stendra and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a stendra NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of stendra suppliers with NDC on PharmaCompass.

    stendra GMP

    stendra Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of stendra GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right stendra GMP manufacturer or stendra GMP API supplier for your needs.

    stendra CoA

    A stendra CoA (Certificate of Analysis) is a formal document that attests to stendra's compliance with stendra specifications and serves as a tool for batch-level quality control.

    stendra CoA mostly includes findings from lab analyses of a specific batch. For each stendra CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    stendra may be tested according to a variety of international standards, such as European Pharmacopoeia (stendra EP), stendra JP (Japanese Pharmacopeia) and the US Pharmacopoeia (stendra USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search